Recursion Pharmaceuticals

RXRX Lead: Phase 2 1 Biotech Distilled article ↓

Most recent annual filing: 2026-02-25

Catalyst timeline

REC-4881 FDA feedback2H 2026REC-4881 FDA feedback, 2H 2026, thesis-defining
REC-1245 Ph1 interim2H 2026REC-1245 Ph1 interim, 2H 2026, notable
REC-7735 Ph1 start2H 2026REC-7735 Ph1 start, 2H 2026, routine
REC-102 corporate update2H 2026REC-102 corporate update, 2H 2026, routine
Tempus agreement corporate updateNov 2026Tempus agreement corporate update, Nov 2026, routine
REC-4881 Ph1 readoutNov 2, 2026REC-4881 Ph1 readout, Nov 2, 2026, major
REC-4881; REC-617; REC-3565 interim1H 2027REC-4881; REC-617; REC-3565 interim, 1H 2027, material
REC-4539 interim2H 2027REC-4539 interim, 2H 2027, notable
Company cash runway guidance updateEarly 2028Company cash runway guidance update, Early 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

Rec-102

REC-102

Small Molecule Target: ENPP1

Hypophosphatasia Preclinical

Familial Adenomatous Polyposis Phase 2 Phase 1b/2 trial oral NCT05552755

REC-1245

Small Molecule Target: RBM39

Solid Tumors Phase 1 Phase 1/2 trial NCT06678659

REC-4539

Small Molecule Target: LSD1

Solid Tumors Phase 1 oral
Acute Myeloid Leukemia Preclinical oral

Technology platforms

Recursion OS

Recursion Operating System — AI-native, end-to-end drug discovery and development platform integrating multimodal biological data generation, AI-powered small molecule synthesis, and AI-enabled clinical development. Disease focus spans oncology, immunology, neuroinflammation, neuroscience, and gastrointestinal cancers. Underpins internal pipeline and partnerships with Sanofi, Merck KGaA, Roche, and Genentech.

ClinTech

Industrialized clinical development platform leveraging causal AI, AI-powered recruitment, intelligent clinical trial design, real-world data integration, and agentic solutions to improve probability of success in clinical trials.

Discontinued (3)

REC-2282 — Neurofibromatosis Type 2 · discontinued as part of May 2025 portfolio prioritization; partnering opportunities being pursued
REC-994 — Cerebral Cavernous Malformation · discontinued as part of May 2025 portfolio prioritization; partnering opportunities being pursued
REC-3964 — Clostridioides Difficile Infection · discontinued as part of May 2025 portfolio prioritization; partnering opportunities being pursued

Biotech Distilled coverage (1)

2026-09-23 Recursion Pharmaceuticals (RXRX) — Scientific Deep Dive for REC-4881, the Recursion OS, and Pipeline Products 🔒 Paid

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.